This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fassnacht, M. Articles by Allolio, B. Search for Related Content PubMed PubMed Citation Articles by Fassnacht, M. Articles by Allolio, B. Related Collections Adrenal and Hypertension Endocrine Oncology

Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma

University of Wuerzburg, Department of Internal Medicine I, Endocrine and Diabetes Unit (M.Fa., S.H., A.-C.K., B.A.), Department of Radiation Oncology (B.P., M.Fl.), and Department of Radiology (W.K.), 97080 Wuerzburg, Germany

Address all correspondence and requests for reprints to: Martin Fassnacht, M.D., Department of Medicine I, Endocrine and Diabetes Unit, University Hospital Wuerzburg, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany. E-mail: fassnacht_m{at}medizin.uni-wuerzburg.de.

Context: Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation. Although radiotherapy is often considered ineffective in the treatment of ACC, the limited number of available studies does not support this statement.

Objective: The objective of the study was investigation of adjuvant tumor bed irradiation in the treatment of ACC.

Design: We performed a retrospective analysis.

Patients: The German ACC Registry (n = 285) was screened for patients who had received tumor bed radiotherapy in an adjuvant setting (no macroscopic evidence for residual disease after surgery). Fourteen patients without distant metastases (World Health Organization stage I, one patient; stage II, seven; stage III, three; and stage IV, three) were matched with 14 patients for resection status, adjuvant mitotane treatment, stage, and tumor size. Median follow-up of patients still alive (n = 15) was 37 months.

Main Outcome Measure: Survival without local recurrence and disease-free survival was the main outcome measure.

Results: Local recurrence was observed in two of 14 patients in the radiotherapy group and in 11 of 14 control patients. The probability to be free of local recurrence 5 yr after surgery differed significantly [79% (95% confidence interval, 53–100) vs. 12% (0–30); P < 0.01]. However, disease-free and overall survival were not significantly different between the two groups. Acute adverse events related to radiotherapy were mostly mild. One patient developed a partial Budd-Chiari syndrome.

Conclusion: These data from the largest series of ACC patients treated with adjuvant tumor bed irradiation suggest that radiotherapy is effective in reducing the high rate of local recurrence in ACC. A randomized trial in high-risk patients is needed to further evaluate the efficacy of radiotherapy as an adjuvant treatment option in ACC.

This article has been cited by other articles:

				L. J. Tacon, P. S. Soon, A. J. Gill, A. S. Chou, A. Clarkson, J. Botling, P. L. H. Stalberg, B. M. Skogseid, B. G. Robinson, S. B. Sidhu, et al. The Glucocorticoid Receptor Is Overexpressed in Malignant Adrenocortical Tumors J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4591 - 4599. [Abstract] [Full Text] [PDF]

				I. Veytsman, L. Nieman, and T. Fojo Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma J. Clin. Oncol., September 20, 2009; 27(27): 4619 - 4629. [Abstract] [Full Text] [PDF]

				W. Fenske, H.-U. Volker, P. Adam, S. Hahner, S. Johanssen, S. Wortmann, M. Schmidt, M. Morcos, H.-K. Muller-Hermelink, B. Allolio, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma Endocr. Relat. Cancer, September 1, 2009; 16(3): 919 - 928. [Abstract] [Full Text] [PDF]

				S. Vuorenoja, B. P. Mohanty, J. Arola, I. Huhtaniemi, J. Toppari, and N. A Rahman Hecate-CG{beta} conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-{alpha} promoter Endocr. Relat. Cancer, June 1, 2009; 16(2): 549 - 564. [Abstract] [Full Text] [PDF]

				I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919. [Abstract] [Full Text] [PDF]

				S. Hahner, A. Stuermer, M. Kreissl, C. Reiners, M. Fassnacht, H. Haenscheid, F. Beuschlein, M. Zink, K. Lang, B. Allolio, et al. [123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2358 - 2365. [Abstract] [Full Text] [PDF]

				P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu Molecular Markers and the Pathogenesis of Adrenocortical Cancer Oncologist, May 1, 2008; 13(5): 548 - 561. [Abstract] [Full Text] [PDF]

				M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380. [Abstract] [Full Text] [PDF]

				L. S. Kirschner Paradigms for adrenal cancer: think globally, act locally. J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4250 - 4252. [Full Text] [PDF]